A phase 1, single-center, double-blind study of AM103 in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2013
At a glance
- Drugs GSK 2190914 (Primary)
- Indications Asthma; Cardiovascular disorders; Respiratory tract disorders
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Amira Pharmaceuticals
- 27 Dec 2011 Actual initiiation date 18 Jun 2007 added and trial location (Netherlands) identified as reported by ISRCTN.
- 27 Dec 2011 Actual end date 31 Oct 2007 added as reported by ISRCTN.
- 02 Nov 2007 Status change from initiated to completed.